Research Collaboration and Exclusive License Agreement - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Target	Dec. 31, 2022 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Deferred revenue current	$ 1,705	$ 5,406
Accounts receivable balance outstanding	0	0
Merck Agreement First Collaboration Target
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable and non-creditable upfront fee	8,000
Initial Transaction Price	11,400
Reimbursable research program funding for collaboration target	3,400
Merck Agreement Second Collaboration Target
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable and non-creditable upfront fee	8,000
Initial Transaction Price	12,000
Reimbursable research program funding for collaboration target	4,000
Aggregate transaction price allocated to unsatisfied performance obligation	$ 3,100
Merck Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Number of collaboration targets | Target	2
Non-refundable and non-creditable upfront fee	$ 8,000
Payable upon selection of second collaboration target	8,000
Milestone payments	285,000
Revenue recognized	8,100	$ 8,600
Deferred revenue current	1,700
Merck Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments per collaboration target	142,500
Milestone payments upon successful completion of certain commercial milestones	$ 350,000